Wiadomości

Lilly Buying Spree Surpasses $32B

Bloomberg

Bloomberg’s Madison Muller joins Dani Burger on “Bloomberg Deals.” Eli Lilly agreed to buy closely held Calytrix Bio in a deal that could be worth up to $1.5 billion, the latest in the drugmaker’s $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses. (Source: Bloomberg)

Przeczytaj pelny brief Veytics

Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.